CLINICAL TRIALS PROFILE FOR IMODIUM A-D EZ CHEWS

All Clinical Trials for IMODIUM A-D EZ CHEWS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075868 ↗	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2003-12-01	RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00075868 ↗	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	2003-12-01	RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00292344 ↗	Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea	Completed	Bausch Health Americas, Inc.	Phase 4	2004-06-01	Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00292344 ↗	Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea	Completed	Valeant Pharmaceuticals International, Inc.	Phase 4	2004-06-01	Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00292344 ↗	Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea	Completed	The University of Texas Health Science Center, Houston	Phase 4	2004-06-01	Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.
NCT00360828 ↗	Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas	Terminated	H. Lee Moffitt Cancer Center and Research Institute	Phase 2	2006-02-01	Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects.
NCT00583531 ↗	Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis	Terminated	Ocera Therapeutics	Phase 2	2007-03-01	This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry. They may continue other previously prescribed treatments (e.g., probiotics and/or nutritional agents) at the discretion of the study doctor. The purpose of the study is to assess whether the investigational medication AST-120 will be a safe and effective treatment for the symptoms of pouchitis, a chronic inflammatory condition, in patients whose symptoms have not responded well to antibiotics. An initial group of 10 patients will be enrolled. If there are no serious side effects associated with the study drug and at least 3 of the 10 patients respond, a second group of 10 patients may be enrolled. Patients will have clinic visits at the start of the study and at week 4. Patients will be checked by phone on a weekly basis for symptom response, compliance and development of side effects. Endoscopies will be performed at the start of the study and at week 4 or early termination.

Clinical Trial Conditions for IMODIUM A-D EZ CHEWS

Condition Name

Condition Name for IMODIUM A-D EZ CHEWS
Intervention	Trials
Diarrhea	5
Fecal Incontinence	3
Travelers' Diarrhea	2
Healthy	2

Condition MeSH

Condition MeSH for IMODIUM A-D EZ CHEWS
Intervention	Trials
Diarrhea	10
Fecal Incontinence	3
Dysentery	2
Short Bowel Syndrome	2

Clinical Trial Locations for IMODIUM A-D EZ CHEWS

Trials by Country

Trials by Country for IMODIUM A-D EZ CHEWS
Location	Trials
United States	59
Mexico	6
Spain	3
Kenya	1
Denmark	1

Trials by US State

Trials by US State for IMODIUM A-D EZ CHEWS
Location	Trials
California	5
Texas	5
North Carolina	4
Missouri	2
Minnesota	2

Clinical Trial Progress for IMODIUM A-D EZ CHEWS

Clinical Trial Phase

Clinical Trial Phase for IMODIUM A-D EZ CHEWS
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for IMODIUM A-D EZ CHEWS
Clinical Trial Phase	Trials
Completed	12
Terminated	5
Withdrawn	2

Clinical Trial Sponsors for IMODIUM A-D EZ CHEWS

Sponsor Name

Sponsor Name for IMODIUM A-D EZ CHEWS
Sponsor	Trials
M.D. Anderson Cancer Center	2
Johnson & Johnson Consumer and Personal Products Worldwide	2
McNeil AB	2

Sponsor Type

Sponsor Type for IMODIUM A-D EZ CHEWS
Sponsor	Trials
Other	29
Industry	18
U.S. Fed	4